Sean Maduck Sells 75,000 Shares of Corcept Therapeutics (NASDAQ:CORT) Stock

Corcept Therapeutics Incorporated (NASDAQ:CORT) insider Sean Maduck sold 75,000 shares of the firm’s stock in a transaction on Wednesday, May 27th. The shares were sold at an average price of $65.59, for a total transaction of $4,919,250.00. Following the sale, the insider owned 8,977 shares in the company, valued at $588,801.43. The trade was a 89.31% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Corcept Therapeutics Trading Up 1.6%

Shares of CORT traded up $1.11 during trading hours on Friday, reaching $69.49. 774,694 shares of the stock traded hands, compared to its average volume of 1,782,915. Corcept Therapeutics Incorporated has a 52-week low of $28.66 and a 52-week high of $91.00. The company’s 50-day moving average price is $47.30 and its two-hundred day moving average price is $52.18. The company has a market cap of $7.46 billion, a P/E ratio of 198.55 and a beta of 0.36.

Corcept Therapeutics (NASDAQ:CORT) last released its earnings results on Thursday, April 30th. The biotechnology company reported ($0.30) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.19). Corcept Therapeutics had a net margin of 6.14% and a return on equity of 7.40%. The firm had revenue of $164.90 million for the quarter, compared to analysts’ expectations of $185.83 million. During the same quarter last year, the firm posted $0.17 EPS. The firm’s quarterly revenue was up 4.9% compared to the same quarter last year. On average, research analysts forecast that Corcept Therapeutics Incorporated will post 0.52 EPS for the current year.

Analysts Set New Price Targets

Several analysts recently issued reports on CORT shares. UBS Group set a $135.00 target price on Corcept Therapeutics in a research note on Thursday. Canaccord Genuity Group boosted their target price on shares of Corcept Therapeutics from $110.00 to $135.00 and gave the stock a “buy” rating in a report on Thursday. Wolfe Research raised shares of Corcept Therapeutics from an “underperform” rating to a “peer perform” rating in a report on Thursday, March 26th. Truist Financial raised shares of Corcept Therapeutics to a “strong-buy” rating in a report on Wednesday, March 25th. Finally, Piper Sandler boosted their target price on shares of Corcept Therapeutics from $73.00 to $88.00 and gave the stock an “overweight” rating in a report on Friday, May 1st. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $88.83.

Key Stories Impacting Corcept Therapeutics

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: Canaccord Genuity raised its price target on Corcept Therapeutics to $135 from $110 and reiterated a buy rating, signaling greater confidence in upside potential. Canaccord Genuity price target update
• Positive Sentiment: HC Wainwright lifted its 2026 earnings estimates for CORT, including higher Q3, Q4, and full-year EPS forecasts, while maintaining a buy rating and $95 target. Higher profit expectations often support the stock. HC Wainwright estimate revisions
• Positive Sentiment: Corcept said it plans to resubmit the NDA for relacorilant in Cushing’s syndrome, which keeps a key pipeline asset alive and appears to be the main business-specific catalyst behind the recent rally. Relacorilant NDA resubmission article
• Neutral Sentiment: Stockholders approved an expanded incentive plan and board-related matters at the 2026 annual meeting; this is supportive of governance but not a major immediate earnings driver. Stockholders approve expanded incentive plan and board

Institutional Investors Weigh In On Corcept Therapeutics

Hedge funds have recently bought and sold shares of the business. Torren Management LLC purchased a new stake in Corcept Therapeutics during the fourth quarter valued at $25,000. Advisory Services Network LLC purchased a new stake in Corcept Therapeutics during the third quarter valued at $25,000. Clearstead Advisors LLC raised its stake in Corcept Therapeutics by 163.6% during the third quarter. Clearstead Advisors LLC now owns 311 shares of the biotechnology company’s stock valued at $26,000 after purchasing an additional 193 shares in the last quarter. Atlas Capital Advisors Inc. purchased a new stake in Corcept Therapeutics during the fourth quarter valued at $31,000. Finally, State of Wyoming raised its stake in Corcept Therapeutics by 29.5% during the first quarter. State of Wyoming now owns 816 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 186 shares in the last quarter. Hedge funds and other institutional investors own 93.61% of the company’s stock.

Corcept Therapeutics Company Profile

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.